Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026437 | 0.91 | ALDH1A1 (0.83) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL13804475 | 0.86 | ALDH1A1 (0.71) | CYP1A2ALDH1A1NPSR1HTTMAPK1 | |
| SCHEMBL3099181 | 0.84 | ALDH1A1 (0.73) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL1372144 | 0.84 | ALDH1A1 (0.73) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL12846701 | 0.83 | HTT (0.71) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL3093579 | 0.83 | ALDH1A1 (0.71) | ALDH1A1NPSR1HTTMAPK1POLB | |
| SCHEMBL4748498 | 0.82 | ALDH1A1 (0.87) | CYP1A2ALDH1A1NPSR1HTTMAPK1 | |
| SCHEMBL61103 | 0.82 | ALDH1A1 (0.87) | CYP1A2ALDH1A1NPSR1HTTMAPK1 | |
| SCHEMBL4544770 | 0.82 | ALDH1A1 (0.65) | CYP1A2ALDH1A1NPSR1HTTMAPK1 | |
| SCHEMBL13612640 | 0.82 | ALDH1A1 (0.72) | ALDH1A1NPSR1HTTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | claimed |
| US-20140336165-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-11-13 | — | — | US | claimed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3912973-A2 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3536687-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-07-14 | — | — | EP | disclosed |
| WO-2021072475-A1 | DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2021-04-22 | — | — | WO | disclosed |
| EP-3536687-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3150593-B1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2964616-B1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-3150593-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | Dana Farber Cancer Institute, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070055064-A1 | Process for the crystallisation of guandinium salts | MERCK PATENT GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055064-A1 | Process for the crystallisation of guandinium salts | MERCK PATENT GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | IPSEN PHARMA S.A.S. (FR) | 2007-02-22 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| US-20070010531-A1 | Substituted pyrazole compounds | MERCK PATENT GMBH (DE) | 2007-01-11 | — | — | US | disclosed |
| WO-2004099125-A1 | METHOD FOR CRYSTALLIZING GUANIDINIUM SALTS | MERCK PATENT GMBH (DE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2003007959-A1 | QUINOXALINE DERIVATIVES WHICH HAVE PARP INHIBITORY ACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055064-A1 | Process for the crystallisation of guandinium salts | GMPS, GUCY1A2, GUCY1A1 | CYP1A2 495/4885ALDH1A1 1522/4885NPSR1 2189/4885 |
| US-20070010531-A1 | Substituted pyrazole compounds | HTR3A, HTR1A, HTR1D | CYP1A2 204/4885ALDH1A1 897/4885NPSR1 20/4885 |
| US-20070043095-A1 | Derivatives of 2-arylimino-2,3-dihydrothiazoles, their preparation processes and their therapeutic use | SSTR2, SSTR5, SSTR3 | CYP1A2 637/4885ALDH1A1 812/4885NPSR1 31/4885 |
| US-20070093509-A1 | Non-basic melanin concentrating hormone receptor-1 antagonists | MCHR1, MCHR2, MC1R | CYP1A2 861/4885ALDH1A1 622/4885NPSR1 20/4885 |
| US-20140336165-A1 | DIHYDROXY AROMATIC HETEROCYCLIC COMPOUND | DAO, DDO, DDC | CYP1A2 159/4885ALDH1A1 117/4885NPSR1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.